BeiGene Q2FY26 Results: Revenue up 30%, guidance raised
- Q2FY26 revenue rose 30% YoY to $1.7 billion; net income hit $237 million
- Brukinsa global sales exceeded $1.2 billion, up 31%, driving top-line growth
- Full-year revenue guidance raised by $300 million to $6.6–$6.8 billion range
- Free cash flow doubled to $435 million; gross margin remained near 90%
- FDA approved Bacalzi for MCL; Brukinsa showed positive Phase 3 Mangrove data
*this image is generated using AI for illustrative purposes only.
BeiGene (NASDAQ: ONC) reported Q2FY26 revenue of $1.7 billion, a 30% increase year-over-year, alongside GAAP earnings per ADS of $2.05, up 144%. The company raised its full-year revenue and GAAP operating income guidance by $300 million and $250 million, respectively.
Brukinsa, the company’s foundational BTK inhibitor, generated over $1.2 billion in global revenues, reflecting 31% growth. This performance was supported by the highest level of sustained new patient starts since launch and strong adoption across five approved indications.
Financial Performance
Total revenue reached $1.7 billion, with gross profit at $1.5 billion and gross margin just under 90%. Operating expenses totaled $1.2 billion, a 13% increase, reflecting investment in clinical programs and commercial growth. Income from operations grew to $325 million.
Net income stood at $237 million, including a previously disclosed tax audit settlement impact of approximately $60 million. Adjusted income from operations increased to $503 million, representing more than 80% growth year-over-year. Free cash flow doubled from the prior-year period to $435 million.
| Metric | Q2FY26 | Change |
|---|---|---|
| Total Revenue | $1.7 billion | +30% YoY |
| Brukinsa Revenue | >$1.2 billion | +31% YoY |
| Net Income | $237 million | N/A |
| Free Cash Flow | $435 million | Doubled YoY |
Regional Breakdown
The US remained the largest market, contributing approximately $899 million in revenue, up 31% year-over-year. China contributed approximately $500 million, growing 17%, with foreign exchange contributing 7% of reported growth due to renminbi strengthening. Europe generated approximately $208 million, rising 37%. Rest of world revenue more than doubled to approximately $73 million.
What the Numbers Show
Brukinsa accounts for more than 70% of total revenue ($1.2 billion vs $1.7 billion), highlighting significant concentration risk despite broad-based portfolio growth. While Tevimbra grew 18% to $229 million and the Amgen in-license portfolio rose 25% to $157 million, Brukinsa remains the primary driver of both top-line expansion and margin scalability.
Pipeline and Guidance
Management raised full-year revenue outlook to $6.6–$6.8 billion and GAAP operating income to $1.0–$1.1 billion. Strategically, BeiGene announced FDA approval of Bacalzi for mantle cell lymphoma and positive Phase 3 Mangrove study results for Brukinsa as a chemo-free treatment option. A $300 million investment is underway to expand its US manufacturing site in Hopewell, New Jersey.
How might the FDA approval of Bacalzi for mantle cell lymphoma impact BeiGene's revenue diversification away from its heavy reliance on Brukinsa?
What are the potential competitive risks to Brukinsa's market share as new BTK inhibitors or chemo-free alternatives enter the pipeline?
Will the $300 million expansion of the US manufacturing site in New Jersey be sufficient to meet projected demand growth, or could supply chain constraints emerge?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
